Literature DB >> 15668854

Efavirenz intoxication due to slow hepatic metabolism.

B Hasse1, H F Günthard, G Bleiber, M Krause.   

Abstract

We describe a human immunodeficiency virus-positive woman who presented with severe psychosis while she was receiving therapy with efavirenz. Her plasma efavirenz level was excessively high. Genetic investigation showed that she was homozygous for the CYP2B6 G516T allele, resulting in slow hepatic metabolism. After the dosage of efavirenz was lowered, all neuropsychiatric symptoms subsided.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15668854     DOI: 10.1086/427031

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  18 in total

1.  Long-term efficacy and safety of efavirenz dose reduction to 200 mg once daily in a Caucasian patient with HIV.

Authors:  Salvador Cabrera Figueroa; Alicia Iglesias Gómez; Almudena Sánchez Martín; María de la Paz Valverde Merino; Alfonso Domínguez-Gil Hurlé; Miguel Cordero Sánchez
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

Review 2.  Neuropsychiatric complications of antiretroviral therapy.

Authors:  Michelle S Cespedes; Judith A Aberg
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 3.  Adherence-resistance relationships to combination HIV antiretroviral therapy.

Authors:  David R Bangsberg; Deanna L Kroetz; Steven G Deeks
Journal:  Curr HIV/AIDS Rep       Date:  2007-05       Impact factor: 5.071

4.  Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals.

Authors:  David J Back; Andrew Owen; Saye H Khoo
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

5.  CYP2B6 983T>C polymorphism is prevalent in West Africa but absent in Papua New Guinea: implications for HIV/AIDS treatment.

Authors:  Rajeev K Mehlotra; Moses J Bockarie; Peter A Zimmerman
Journal:  Br J Clin Pharmacol       Date:  2007-03-28       Impact factor: 4.335

6.  Optimizing efavirenz treatment: CYP2B6 genotyping or therapeutic drug monitoring?

Authors:  Margalida Rotger; Amalio Telenti
Journal:  Eur J Clin Pharmacol       Date:  2008-01-11       Impact factor: 2.953

7.  Allele and genotype frequencies of CYP2B6 in a Turkish population.

Authors:  Nazan Yuce-Artun; Gulcin Kose; H Sinan Suzen
Journal:  Mol Biol Rep       Date:  2014-02-22       Impact factor: 2.316

8.  Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data.

Authors:  Katie R Mollan; Marlene Smurzynski; Joseph J Eron; Eric S Daar; Thomas B Campbell; Paul E Sax; Roy M Gulick; Lumine Na; Lauren O'Keefe; Kevin R Robertson; Camlin Tierney
Journal:  Ann Intern Med       Date:  2014-07-01       Impact factor: 25.391

Review 9.  Complex Drug-Drug-Gene-Disease Interactions Involving Cytochromes P450: Systematic Review of Published Case Reports and Clinical Perspectives.

Authors:  Flavia Storelli; Caroline Samer; Jean-Luc Reny; Jules Desmeules; Youssef Daali
Journal:  Clin Pharmacokinet       Date:  2018-10       Impact factor: 6.447

Review 10.  Neurological and psychiatric adverse effects of antiretroviral drugs.

Authors:  Michael S Abers; Wayne X Shandera; Joseph S Kass
Journal:  CNS Drugs       Date:  2014-02       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.